NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

全球生物相似藥市場

Biosimilars

出版商 Global Industry Analysts, Inc. 商品編碼 240198
出版日期 內容資訊 英文 175 Pages
商品交期: 最快1-2個工作天內
價格
全球生物相似藥市場 Biosimilars
出版日期: 2021年04月01日內容資訊: 英文 175 Pages
簡介

本報告提供全球生物相似藥市場相關調查,市場現狀與今後的成長預測,各地區趨勢,及加入此市場的主要企業簡介等資料彙整。

第1章 簡介,調查方法,產品定義

第2章 產業概要

  • 概要
  • 全球醫療領域
  • 雖有課題但是有高潛力
  • 歐美推動銷售額擴大
  • 新興市場成長的機會
  • 研究開發投資
  • 經濟方案

第3章 值得一提的市場趨勢,促進成長要素,課題

  • 許多產品核可擴大市場收益
  • 歐洲的認證
  • 美國的核准
  • 開發中產品
  • 生物醫藥品的專利失效
  • 成本控制策略 其他

第4章 產品概要

  • 簡介
  • 概要
  • 生物相似藥的特性
  • 生物相似藥的開發週期
  • 產業進入者

第5章 競爭環境

  • 主要企業
  • 印度和中國的企業的機會
  • 生物相似藥的滲透
  • 生物非專利的進入障礙比較
  • 授權契約與開發、商品化聯盟
  • 主要企業

第6章 全球市場預測

第7章 各地區市場趨勢

  • 美國
  • 日本
  • 歐洲
  • 亞太地區
  • 南美
  • 中東、非洲
  • 撒哈拉以南非洲
  • 加拿大

第8章 企業簡介

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-6201

Abstract:

Global Biosimilars Market to Reach $45.5 Billion by 2027

Amid the COVID-19 crisis, the global market for Biosimilars estimated at US$7.5 Billion in the year 2020, is projected to reach a revised size of US$45.5 Billion by 2027, growing at a CAGR of 29.3% over the analysis period 2020-2027. Recombinant Non-glycosylated Proteins, one of the segments analyzed in the report, is projected to record a 28.9% CAGR and reach US$19.9 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Recombinant Glycosylated Proteins segment is readjusted to a revised 33.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $2.3 Billion, While China is Forecast to Grow at 28.6% CAGR

The Biosimilars market in the U.S. is estimated at US$2.3 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$7.8 Billion by the year 2027 trailing a CAGR of 28.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 26.1% and 25.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 20.7% CAGR.

Recombinant Peptides Segment to Record 23.4% CAGR

In the global Recombinant Peptides segment, USA, Canada, Japan, China and Europe will drive the 23.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.4 Billion in the year 2020 will reach a projected size of US$6.2 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$5.4 Billion by the year 2027.

Select Competitors (Total 71 Featured) -

  • Allergan Plc
  • Amgen Inc.
  • Biocon Ltd.
  • Biopartners GmbH
  • Boehringer Ingelheim International GmbH
  • Celltrion Inc.
  • Dr. Reddy`s Laboratories Ltd.
  • Eli Lilly and Company
  • Fresenius Kabi
  • Intas Pharmaceuticals Ltd.
  • Mylan NV
  • Pfizer Inc.
  • Samsung Bioepis Co. Ltd.
  • Sandoz International GmbH
  • STADA Arzneimittel AG
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Biosimilars: An Introductory Prelude
    • Recent Market Activity
    • World Healthcare Sector Gears Up for Biosimilar Wave
    • Biosimilars Offer Great Promise Despite Challenges
    • The US & Europe Drive Momentum in Worldwide Biosimilars Sales
    • Emerging Markets also Offer Robust Growth Opportunities
    • R&D Funding: Crucial for Future Expansion of Biosimilars Market
    • Prevailing Economic Scenario Favors Funding Pattern
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
    • Allergan Plc (Ireland)
    • Amgen, Inc. (USA)
    • Biocon Ltd. (India)
    • Biopartners GmbH (Switzerland)
    • Boehringer Ingelheim International GmbH (Germany)
    • Celltrion, Inc. (South Korea)
    • Dr. Reddy's Laboratories Ltd. (India)
    • Eli Lilly and Company (USA)
    • Fresenius Kabi (Germany)
    • Intas Pharmaceuticals Ltd. (India)
    • Mylan N.V. (USA)
    • Pfizer, Inc. (USA)
    • Samsung Bioepis Co., Ltd. (Korea)
    • Sandoz International GmbH (Germany)
    • STADA Arzneimittel AG (Germany)
    • Teva Pharmaceutical Industries Ltd. (Israel)
  • 3. MARKET TRENDS & DRIVERS
    • Slew of Product Approvals Scale Up Market Revenues
    • Biosimilar Approvals in Europe (as of H1 2018)
    • Biosimilar Approvals in the US (as of H1 2018)
    • Pipeline Biosimilar Products in the US (as of H1 2018)
    • Biosimilar Approvals in South Korea (as of H1 2018)
    • Patent Expiry of Major Biopharmaceutical Drugs Leads Way for Biosimilars
    • Patent Expiries of Major Biopharmaceutical Drugs in the US and Europe
    • Cost Containment Measures Put Focus on Biosimilars
    • High Cost of Biologics - Favorable for Biosimilars
    • Efforts to Push Up Biosimilar Adoption Aid Market Expansion
    • Increasing Share of Biotech Drugs to Drive Biosimilars Market
    • Progressive Regulatory Framework Accelerates Product Approvals & Subsequently Market Revenues
    • Specific Guidelines for Biosimilars in Various Countries with Year of Publication
    • Biosimilars Regulatory Agencies in Select Regional Markets
    • Improvement in Nomenclature & Interchangeability Enhance Appeal & Image of Biosimilars
    • Human Insulin Biosimilars Eye Potential Opportunities
    • Monoclonal Antibodies - A Key Segment for Biosimilars
    • Approved Monoclonal Antibodies (2014-2017)
    • Rituximab Biosimilars to Proliferate the Market
    • Growing Incidence of Chronic Diseases & Ageing Population Widen Prospects for Biosimilars
    • Growing Biosimilars Market - A Clear Advantage for Bioseparation Technologies
    • Growth Restraints
    • Lack of Uniform Regulations
    • High Lead-time
    • High Manufacturing Costs
    • Difficulties in Delivery & Commercialization
    • Automatic Substitution
    • Biobetters: A Potential Industry Challenge
    • Other Impediments to Market Acceptance
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World 7-Year Perspective for Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
    • TABLE 3: World Current & Future Analysis for Recombinant Non-glycosylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 4: World 7-Year Perspective for Recombinant Non-glycosylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 5: World Current & Future Analysis for Recombinant Glycosylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 6: World 7-Year Perspective for Recombinant Glycosylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Recombinant Peptides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World 7-Year Perspective for Recombinant Peptides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 9: World Current & Future Analysis for Blood Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 10: World 7-Year Perspective for Blood Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 11: World Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 12: World 7-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Chronic Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World 7-Year Perspective for Chronic Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 15: World Current & Future Analysis for Autoimmune Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 16: World 7-Year Perspective for Autoimmune Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 17: World Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 18: World 7-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 19: USA Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 20: USA 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
    • TABLE 21: USA Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 22: USA 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027
  • CANADA
    • TABLE 23: Canada Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 24: Canada 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
    • TABLE 25: Canada Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: Canada 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027
  • JAPAN
    • TABLE 27: Japan Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 28: Japan 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
    • TABLE 29: Japan Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 30: Japan 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027
  • CHINA
    • TABLE 31: China Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: China 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
    • TABLE 33: China Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 34: China 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027
  • EUROPE
    • TABLE 35: Europe Current & Future Analysis for Biosimilars by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 36: Europe 7-Year Perspective for Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
    • TABLE 37: Europe Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Europe 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
    • TABLE 39: Europe Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 40: Europe 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027
  • FRANCE
    • TABLE 41: France Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 42: France 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
    • TABLE 43: France Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: France 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027
  • GERMANY
    • TABLE 45: Germany Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 46: Germany 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
    • TABLE 47: Germany Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 48: Germany 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027
  • ITALY
    • TABLE 49: Italy Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Italy 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
    • TABLE 51: Italy Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 52: Italy 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027
  • UNITED KINGDOM
    • TABLE 53: UK Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 54: UK 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
    • TABLE 55: UK Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: UK 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027
  • REST OF EUROPE
    • TABLE 57: Rest of Europe Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 58: Rest of Europe 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
    • TABLE 59: Rest of Europe Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 60: Rest of Europe 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 61: Asia-Pacific Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: Asia-Pacific 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
    • TABLE 63: Asia-Pacific Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 64: Asia-Pacific 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027
  • REST OF WORLD
    • TABLE 65: Rest of World Current & Future Analysis for Biosimilars by Product Type - Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 66: Rest of World 7-Year Perspective for Biosimilars by Product Type - Percentage Breakdown of Value Sales for Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins and Recombinant Peptides for the Years 2020 & 2027
    • TABLE 67: Rest of World Current & Future Analysis for Biosimilars by Disease - Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Rest of World 7-Year Perspective for Biosimilars by Disease - Percentage Breakdown of Value Sales for Blood Disorders, Oncology, Chronic Diseases, Autoimmune Diseases and Other Diseases for the Years 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 71